Meet Ascendia Pharmaceutical Solutions at CPHI Milan 2026

Ascendia Pharmaceutical Solutions will attend CPHI Milan 2026, taking place October 6-8 at Fiera Milano in Italy. Founder and CEO Jingjun (Jim) Huang, PhD, and Chief Commercial Officer Robert Bloder will be available throughout the conference to meet with prospective partners and existing clients.

The meetings will focus on development strategy, formulation challenges, manufacturing planning, and the technical requirements involved in advancing pharmaceutical programs through the clinical and commercial lifecycle.

For companies evaluating a new development or manufacturing partner, CPHI Milan provides an opportunity to discuss specific program requirements directly with Ascendia Pharmaceutical Solutions leadership. Existing clients can also use the conference to address upcoming development priorities, manufacturing plans, and opportunities to expand or advance current programs.

Connect Directly With Ascendia Pharmaceutical Solutions Leadership

Jim Huang and Robert Bloder will host meetings with pharmaceutical and biotechnology companies throughout the conference.

Direct access to executive leadership enables focused, decision-oriented conversations around sponsor priorities. Discussions can address formulation requirements, dosage form selection, analytical development, clinical trial material manufacturing, scale-up, technology transfer, and commercial manufacturing preparation.

For prospective partners, these conversations can help establish whether Ascendia Pharmaceutical Solutions has the technical and manufacturing capabilities required for a specific program. For existing clients, meetings can provide an opportunity to align on upcoming development milestones and manufacturing requirements.

Supporting Drug Development From Preformulation Through Commercialization

Ascendia Pharmaceutical Solutions supports pharmaceutical and biotechnology programs across the drug development lifecycle, from preformulation and formulation development through clinical manufacturing, scale-up, technology transfer, and commercial manufacturing preparation.

The company's capabilities include analytical method development and validation, formulation development, clinical trial material manufacturing, scale-up activities, and technology transfer. This integrated approach allows development and manufacturing considerations to be addressed as programs progress.

Ascendia Pharmaceutical Solutions supports multiple dosage forms and routes of administration, including oral solid dose, sterile injectables, and ophthalmics, among others.

Addressing Complex Formulation Challenges

Formulation challenges can affect drug product performance, manufacturability, bioavailability, and the ability to scale a process. Ascendia Pharmaceutical Solutions provides preformulation and formulation development services based on the characteristics and requirements of each molecule.

The company also offers specialized formulation technologies for programs involving challenges with solubility, dissolution, and drug delivery. These technologies include approaches involving nano-emulsions, lipid nanoparticles, amorphous solid dispersions, and nano-sized drug particles.

Addressing these considerations early can help sponsors establish development strategies that account for both product performance and future manufacturing requirements.

Connecting Development Strategy With Manufacturing Planning

Manufacturing considerations become increasingly important as pharmaceutical programs advance through clinical development. Process scalability, analytical requirements, manufacturing controls, equipment, technology transfer, and commercial production requirements can influence development decisions well before a product reaches commercial manufacturing.

Ascendia Pharmaceutical Solutions supports clinical trial material manufacturing and scale-up while helping sponsors plan for later-stage manufacturing requirements. This includes manufacturing support for injectable and oral dosage forms and analytical development services that support formulation and manufacturing programs.

Early alignment between development and manufacturing can help identify potential scale-up and technology transfer requirements before they create challenges later in the program.

Discussions for Prospective Partners and Existing Clients

CPHI Milan meetings with Ascendia Pharmaceutical Solutions can be tailored to the needs of each organization.

Prospective partners can discuss new molecules requiring preformulation or formulation development, existing formulations presenting manufacturing challenges, clinical-stage programs requiring manufacturing support, or programs approaching scale-up and commercial planning.

Existing clients can use the opportunity to discuss current program priorities, upcoming development milestones, manufacturing requirements, technology transfer, and potential next steps.

These conversations can also address specialized dosage forms, analytical method development and validation, and strategies for connecting clinical development with future commercial manufacturing.

Ascendia Pharmaceutical Solutions leadership will be available at CPHI Milan to meet with pharmaceutical and biotechnology companies throughout the conference.

Prospective partners and existing clients should schedule time with Robert Bloder and Jim Huang in advance to discuss their development, formulation, and manufacturing priorities.

A focused meeting can provide an opportunity to review a specific program, identify technical and manufacturing requirements, and determine how Ascendia Pharmaceutical Solutions can support the next stage of development.